Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entryWESTBY, Mike; SMITH-BURCHNELL, Caroline; MORI, Julie et al.Journal of virology. 2007, Vol 81, Num 5, pp 2359-2371, issn 0022-538X, 13 p.Article

Susceptibility of HIV Type 2 Primary Isolates to CCR5 and CXCR4 Monoclonal Antibodies, Ligands, and Small Molecule InhibitorsESPIRITO-SANTO, Maria; SANTOS-COSTA, Quirina; CALADO, Marta et al.AIDS research and human retroviruses. 2012, Vol 28, Num 5, pp 478-485, issn 0889-2229, 8 p.Article

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityDORR, Patrick; WESTBY, Mike; WEBSTER, Rob et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 11, pp 4721-4732, issn 0066-4804, 12 p.Article

Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5 : Effects of viral diversity, target cell and receptor densityWILLEY, Samantha; PETERS, Paul J; SULLIVAN, W. Matthew et al.Antiviral research. 2005, Vol 68, Num 2, pp 96-108, issn 0166-3542, 13 p.Article